Table 3.
COPD Medications Prescribed by Pulmonologists and Primary Care Physicians
| Currently prescribed COPD treatment, n (%) | PCP patients | Pulmonologist patients |
|---|---|---|
| N = 408 | N = 392 | |
| ICS/LABA only | 128 (31.4) | 85 (21.7) |
| LAMA only | 59 (14.5) | 45 (11.5) |
| LAMA/LABA only | 47 (11.5) | 62 (15.8) |
| ICS/LABA + LAMA | 56 (13.7) | 61 (15.6) |
| ICS/LAMA/LABA only | 29 (7.1) | 55 (14.0) |
| Short-acting only | 34 (8.3) | 24 (6.1) |
| ICS only | 6 (1.5) | 8 (2.0) |
| LABA only | 2 (0.5) | 11 (2.8) |
| LABA + LAMA | 3 (0.7) | 3 (0.8) |
| ICS + LABA | 1 (0.3) | 5 (1.3) |
| ICS + LAMA/LABA | 3 (0.7) | 3 (0.8) |
| ICS + LAMA | 3 (0.7) | 3 (0.8) |
| LAMA/LABA + LAMA | 3 (0.7) | 0 (0.0) |
| ICS + LABA + LAMA | 0 (0.0) | 5 (1.3) |
| ICS/LABA + ICS | 1 (0.3) | 3 (0.8) |
| LAMA/LABA + ICS/LABA | 1 (0.3) | 0 (0.0) |
| Other | 32 (7.8) | 19 (4.9) |
Notes: patients could be treated by multiple physician types; however, the data in this table are grouped according to the physician type who provided the information via the survey. Classifications with a slash (/) indicate combination medications, a plus (+) indicates separate inhalers. Maintenance treatment classes may also include the use of short-acting treatments.
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; PCP, primary care physician.